![Pierre Léonard](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Pierre Léonard
Corporate Officer/Principal at Enobia Pharma, Inc.
Profile
Pierre Léonard is currently working as the VP-Drug Development & Program Management at Enobia Pharma, Inc. He holds a doctorate degree from the University of Cincinnati (Ohio).
Pierre Léonard active positions
Companies | Position | Start |
---|---|---|
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Corporate Officer/Principal | 01/07/2009 |
Training of Pierre Léonard
University of Cincinnati (Ohio) | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 1 |
---|---|
Enobia Pharma, Inc.
![]() Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
- Stock Market
- Insiders
- Pierre Léonard